Repositioning Candidate Details

Candidate ID: R0468
Source ID: DB01252
Source Type: investigational
Compound Type: small molecule
Compound Name: Mitiglinide
Synonyms: Mitiglinide
Molecular Formula: C19H25NO3
SMILES: [H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O
Structure:
DrugBank Description: Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.
CAS Number: 145375-43-5
Molecular Weight: 315.413
DrugBank Indication: For the treatment of type 2 diabetes.
DrugBank Pharmacology: Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs. It is approved for use in Japan but has not yet gained FDA approval.
DrugBank MoA: Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.
Targets: ATP-binding cassette sub-family C member 8 inhibitor; Peroxisome proliferator-activated receptor gamma agonist
Inclusion Criteria: Target associated